0001193125-24-040727.txt : 20240221 0001193125-24-040727.hdr.sgml : 20240221 20240221074700 ACCESSION NUMBER: 0001193125-24-040727 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240221 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 24656407 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 8-K 1 d742672d8k.htm 8-K 8-K
REPLIGEN CORP false 0000730272 0000730272 2024-02-21 2024-02-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 21, 2024

 

 

REPLIGEN CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-14656   04-2729386

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453

(Address of principal executive offices, including zip code)

(781) 250-0111

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.01 per share   RGEN   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On February 21, 2024, Repligen Corporation announced its financial results for the fourth quarter and year end December 31, 2023. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press Release by Repligen Corporation, dated February 21, 2024
104    Cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    REPLIGEN CORPORATION
Date: February 21, 2024     By:  

/s/ Tony J. Hunt

      Tony J. Hunt
      Chief Executive Officer
 EX-99.1 2 d742672dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO      

Repligen Corporation

41 Seyon Street

Building #1, Suite 100

Waltham, Massachusetts 02453

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

 

  •  

Reports fourth quarter revenue of $156 million and full year revenue of $639 million

 

  •  

Continued strength in orders with fourth quarter book-to-bill ratio of 1.03

WALTHAM, Mass., February 21, 2024 — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024.

Tony J. Hunt, Chief Executive Officer of Repligen said, “During the fourth quarter, we again saw order strength, driven by our Filtration and Analytics franchises and continued momentum from new modality accounts, which reflects the differentiated nature of our products in this market. We are pleased to report that for the second quarter in a row, our book-to-bill ratio was above 1.0, at 1.03 for the fourth quarter. Revenue for the quarter came in as expected with a nice contribution from Metenova of $5 million, very much in-line with our expectations. While there are still pockets of headwinds and challenging macro factors in China, we remain optimistic that our markets will improve as we advance through 2024, with growth accelerating in the second half of the year.”

FOURTH QUARTER BUSINESS HIGHLIGHTS

 

  •  

Positive momentum in new modalities, inclusive of cell and gene therapies, with fourth quarter revenue up 5% sequentially, and up 9% year-over-year

 

  •  

Closed acquisition of mixing innovator Metenova AB, expanding our Fluid Management offering; achieved revenue target of $5 million in the fourth quarter

 

  •  

Launched TangenX® SC, the industry’s first holder-free, self-contained Tangential Flow Filtration (TFF) device; a milestone achievement in the advancement of downstream flat sheet TFF technology for ultrafiltration and diafiltration (UF/DF)

 

  •  

Strengthened our balance sheet through a private convertible transaction of $600 million aggregate principal amount of 1.00% convertible senior notes

 

  •  

Published our Sustainability report “Making an Impact”, highlighting the company’s progress across numerous environmental, social and governance (ESG) initiatives

 

1

FINANCIAL PERFORMANCE

 

  •  

Revenue. For Q4 2023, total revenue was $155.7 million, compared to $186.8 million for 2022. Base revenue (non-GAAP) for Q4 2023 was $142.1 million, compared to $163.0 million for Q4 2022.

For the full year 2023, total revenue was $638.8 million, compared to $801.5 million for 2022. Base revenue (non-GAAP) for 2023 was $599.1 million, compared to $660.5 million for 2022.

 

  •  

Gross profit. For Q4 2023, our gross profit (GAAP) was $67.6 million compared to $96.1 million for Q4 2022. Adjusted gross profit (non-GAAP) for Q4 2023 was $76.5 million compared to $96.1 million for Q4 2022. Gross profit (GAAP) includes $7.7 million in one-time restructuring charges, comprised primarily of inventory adjustments and including asset relocation and severance costs.

For the full year 2023, gross profit (GAAP) was $284.8 million, compared to $455.7 million for the full year 2022. Adjusted gross profit (non-GAAP) for the full year 2023 was $316.5 million, compared to $456.9 million for 2022.

 

  •  

(Loss) Income from operations. For Q4 2023, loss from operations (GAAP) was ($0.9) million, compared to income from operations of $48.8 million for Q4 2022. Adjusted income from operations (non-GAAP) for Q4 2023 was $18.8 million, compared to $41.1 million for Q4 2022.

For the full year 2023, income from operations (GAAP) was $54.6 million, compared to $224.7 million for the full year 2022. Adjusted income from operations (non-GAAP) for the full year 2023 was $94.3 million, compared to $232.2 million for 2022.

 

  •  

Net (loss) income. For Q4 2023, net loss (GAAP) was ($25.5) million, compared to net income (GAAP) of $48.7 million for Q4 2022. Adjusted net income (non-GAAP) for Q4 2023 was $18.8 million compared to $39.1 million for Q4 2022.

For the full year 2023, net income (GAAP) was $41.6 million, compared to $186.0 million for full year 2022. Adjusted net income (non-GAAP) for 2023 was $98.4 million compared to $188.6 million for 2022.

 

  •  

(Loss) Earnings per share. For Q4 2023, loss per share (GAAP) was ($0.46) per basic share and fully diluted basis, compared to $0.85 on a fully diluted basis for Q4 2022. Adjusted earnings per share (non-GAAP) for Q4 2023 was $0.33 on a fully diluted basis, compared to $0.68 for Q4 2022.

 

2

For the full year 2023, earnings per share (GAAP) was $0.74 on a fully diluted basis, compared to $3.24 for 2022. Adjusted earnings per share (non-GAAP) for 2023 was $1.75 on a fully diluted basis, compared to $3.28 for 2022.

MARGIN SUMMARY

 

GAAP Margins

      Q4 2023       Q4 2022       2023       2022  

Gross Margin

      43.4 %      51.4 %      44.6 %      56.9 % 

Operating (EBIT) Margin

      (0.6 %)      26.1 %      8.5 %      28.0 % 

 

Adjusted (non-GAAP) Margins

      Q4 2023       Q4 2022       2023       2022  

Gross Margin

      49.1 %      51.5 %      49.5 %      57.0 % 

Operating (EBIT) Margin

      12.1 %      22.0 %      14.8 %      29.0 % 

EBITDA Margin

      16.8 %      26.3 %      20.0 %      30.8 % 

CASH POSITION

 

  •  

Our cash, cash equivalents and short-term investments at December 31, 2023, were $751.3 million, compared to $623.8 million at December 31, 2022.

FINANCIAL GUIDANCE FOR FISCAL YEAR 2024

Our financial guidance for the fiscal year 2024 is based on expectations for our existing business. Our GAAP and Adjusted (non-GAAP) guidance includes the expected impact of businesses acquired in 2023 (FlexBiosys and Metenova) and excludes the impact of any potential business acquisitions in 2024, and future fluctuations in foreign currency exchange rates.

 

    

CURRENT GUIDANCE

(at February 21, 2024)

FY 2024    GAAP    Adjusted (non-GAAP)

Total Reported Revenue

    $620M - $650M    $620M - $650M

Year-over-Year Change

    (3%) - 2%    (3%) - 2%

Base Revenue Growth

    -    (1%) - 4%

Gross Margin

    49% - 50%    49% - 50%

Income from Operations

    $33M - $38M    $83M - $88M

Operating Margin

    5% - 6%    13% - 14%

Other Income (Expense)

    $2M - $3M    $18M - $19M

Adjusted EBITDA Margin

    -    18% - 19%

Tax Rate on Pre-Tax Income

    26%    21%

Net Income

    $26M - $30M    $80M - $84M

Earnings Per Share - Diluted

    $0.46 - $0.53    $1.42 - $1.49

 

3

Our non-GAAP net income guidance for the fiscal year 2024 reflects $54.2 million in adjustments, as referred to in the non-GAAP reconciliation table included later in this press release.

Conference Call and Webcast Access

Repligen will host a conference call and webcast today, February 21, 2024, at 8:30 a.m. ET, to discuss fourth quarter 2023 financial results, corporate developments and financial guidance for the year 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 4526890.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release: book-to-bill ratios, base business revenue growth, adjusted gross profit, adjusted gross margin and adjusted operating margin; adjusted cost of sales; adjusted R&D expense; adjusted SG&A expense; adjusted pre-tax income; adjusted income from operations; adjusted net income; adjusted earnings per share-diluted; adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA margin. The Company provides base revenue and base revenue growth rates, which exclude COVID-related revenue, and the impact of acquisition revenue for current year periods that have no prior year comparables, to facilitate a comparison of its current revenue performance. The Company provides the impact of foreign currency translation, to enable determination of revenue growth rates at constant currency, which exclude the impact of foreign currency translation, in order to facilitate a comparison of its current revenue performance to its past revenue performance. To calculate the impact of foreign currency translation, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period.

 

4

The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: inventory step-up charges; acquisition and integration costs; restructuring charges including the costs of severance; inventory adjustments and accelerated depreciation among other charges; contingent consideration related to the Company’s acquisitions; intangible amortization costs; loss on extinguishment of debt; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; and, the related impact on tax of non-GAAP charges. These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

NOTE:

All reconciliations of above GAAP figures (reported or guidance) to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. When analyzing the Company’s operating performance and guidance investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

Forward-Looking Statement

This release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this release which are not strictly historical statements, including, among others; any express or implied statements or guidance regarding current or future financial performance and position, including our year 2024 financial guidance and related assumptions; expected demand in the markets in which we operate (including the belief that such markets will improve and the impact of such improvement on our business); the expected performance of our business; planned efficiencies and results from our restructuring and rebalancing activities; the expected performance and success of our strategic partnerships and integration of our acquired businesses, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” “projected,” “estimated” or “could” and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, risks associated with our restructuring activities and our ability to successfully rebalance our organization; our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds, including to achieve our adjusted 2024 financial guidance; our ability to develop and commercialize products and the market acceptance of our

 

5

products; our ability to successfully integrate any acquired businesses (including Metenova and FlexBiosys) into our business and achieve the expected benefits of such acquisitions; that demand for our products could continue to decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; the lasting effects of COVID-19 on our business operations and the operations of our customers and suppliers; our volatile stock price; and other risks detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including Annual Report on Form 10-K for the year ended December 31, 2022 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and current reports on Form 8-K, as well as our upcoming Annual Report on Form 10-K for the year ended December 31, 2023. Actual results may differ materially from those Repligen contemplated by these forward-looking statements; therefore, you should not rely on any of these forward-looking statements. These forward-looking statements reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of new information, future development or otherwise, that occur after the date hereof except as required by law.

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881

investors@repligen.com

 

6

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share data)

 

     Three Months Ended
December 31,		     Twelve Months Ended
December 31,		  
     2023     2022     2023     2022  

Revenue:

         

Product revenue

    $ 155,471     $ 186,515     $ 638,381     $ 801,183  

Royalty and other revenue

      272       247       383       353  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total revenue

      155,743       186,762       638,764       801,536  

Costs and expenses:

         

Cost of product revenue

      88,136       90,700       353,922       345,830  

Research and development

      10,285       11,113       42,722       43,936  

Selling, general and administrative

      57,512       53,237       218,113       215,829  

Contingent consideration

      697       (17,125 )      (30,569 )      (28,729 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  
     156,630       137,925       584,188       576,866  
  

 

 

    

 

 

    

 

 

    

 

 

  

(Loss) Income from operations

      (887 )      48,837       54,576       224,670  

Investment income

      6,023       4,016       24,135       6,978  

Interest expense

      (1,138 )      (270 )      (1,951 )      (1,162 ) 

Loss on extinguishment of debt

      (12,676 )      —        (12,676 )      —   

Amortization of debt issuance costs*

      (6,702 )      (455 )      (8,075 )      (1,815 ) 

Other income (expenses), net

      6,623       858       8,123       (9,531 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

(Loss) income before income taxes

      (8,757 )      52,986       64,132       219,140  

Income tax provision

      16,731       4,257       22,555       33,181  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net (loss) income

    $ (25,488 )    $ 48,729     $ 41,577     $ 185,959  
  

 

 

    

 

 

    

 

 

    

 

 

  

(Loss) earnings per share:

         

Basic

    $ (0.46 )    $ 0.88     $ 0.75     $ 3.35  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted*

    $ (0.46 )    $ 0.85     $ 0.74     $ 3.24  
  

 

 

    

 

 

    

 

 

    

 

 

  

Weighted average shares outstanding:

         

Basic

      55,815,666       55,542,248       55,719,860       55,460,232  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted*

      55,815,666       57,105,172       56,377,319       57,455,275  
  

 

 

    

 

 

    

 

 

    

 

 

  

 

*

Under ASU 2020-06, the Company is required to reflect the dilutive effect of the 2019 Notes by application of the if-converted method. Prior to filing the Second Supplemental Indenture on March 4, 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the weighted average twelve months ended December 31, 2022 diluted EPS calculation. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion principal in cash and only the premium in shares of the Company’s common stock. Therefore, from March 5, 2022 to March 31, 2022 the Company included 980,525 shares in the denominator of the weighted average twelve months ended December 31, 2022 diluted EPS calculation. Under the if-converted method, the Company was also required to exclude amortization of debt issuance cost and interest charges applicable to the convertible debt from the numerator of the diluted EPS calculation for the period from January 1, 2022 to March 4, 2022, assuming the interest on convertible debt was never recognized for that period. For the twelve months ended December 31, 2022 the Company excluded amortization of debt issuance costs and interest charges for the period January 1, 2022 to March 4, 2022 of $0.4 million (tax effected) from the numerator.

 

Balance Sheet Data:    December 31,
2023		      December 31,
2022		  

Cash, cash equivalents and marketable securities

    $ 751,323      $ 623,757  

Working capital

      952,881        593,922  

Total assets

      2,824,411        2,524,658  

Long-term obligations

      695,046        209,762  

Accumulated earnings

      438,849        397,272  

Stockholders’ equity

      1,971,203        1,910,700  

 

7

REPLIGEN CORPORATION

RECONCILIATIONS OF GAAP to NON-GAAP FINANCIAL MEASURES

(Unaudited, amounts in thousands, except percentage and per share data)

Reconciliation of Reported Revenue Growth to Organic Revenue Growth (Non-GAAP)

 

     Three Months Ended
December 31,		     Twelve Months Ended
December 31,		  
     2023     2023  

REPORTED REVENUE GROWTH

      (17 %)      (20 %) 

Less: Acquisition Growth

      3 %      1 % 

Less: Currency Exchange

      1 %      0 % 
  

 

 

    

 

 

  

ORGANIC REVENUE GROWTH (NON-GAAP)

      (21 %)      (21 %) 
  

 

 

    

 

 

  

Reconciliation of Total Revenue (GAAP) to Base Revenue (Non-GAAP)

 

     Three Months Ended
December 31,		     % Change
2023 v 2022		     Twelve Months Ended
December 31,		     % Change
2023 v 2022		  
     2023     2022(2)     2023     2022(2)  

GAAP TOTAL REVENUE

    $ 155,743     $ 186,762       (17 %)    $ 638,764     $ 801,536       (20 %) 

COVID Revenue

      (8,007 )      (23,802 )      (66 %)      (32,216 )      (141,067 )      (77 %) 

Inorganic M&A

      (5,670 )      —        100 %      (7,433 )      —        100 % 
  

 

 

    

 

 

      

 

 

    

 

 

    

BASE REVENUE (NON-GAAP) (1)

   $ 142,066     $ 162,960       (13 %)    $ 599,115     $ 660,469       (9 %) 
  

 

 

    

 

 

      

 

 

    

 

 

    

Reconciliation of GAAP (Loss) Income from Operations to Adjusted Income from Operations (Non-GAAP)

 

     Three Months Ended
December 31,		     Twelve Months Ended
December 31,		  
     2023     2022     2023     2022  

GAAP (LOSS) INCOME FROM OPERATIONS

    $ (887 )    $ 48,837     $ 54,576     $ 224,670  

ADJUSTMENTS TO (LOSS) INCOME FROM OPERATIONS:

         

Inventory step-up charges

      1,238       —        1,238       —   

Acquisition and integration costs

      934       2,111       5,861       9,253  

Restructuring costs(3)

      8,188       —        32,200       —   

Contingent consideration

      697       (17,125 )      (30,569 )      (28,729 ) 

Intangible amortization

      8,651       7,304       30,981       27,016  
  

 

 

    

 

 

    

 

 

    

 

 

  

ADJUSTED INCOME FROM OPERATIONS (NON-GAAP)

    $ 18,821     $ 41,127     $ 94,287     $ 232,210  
  

 

 

    

 

 

    

 

 

    

 

 

  

 

8

Reconciliation of GAAP Net (Loss) Income to Adjusted Net Income (Non-GAAP)

 

     Three Months Ended
December 31,		      Twelve Months Ended
December 31,		  
     2023      2022      2023      2022  

GAAP NET (LOSS) INCOME

    $ (25,488 )     $ 48,729      $ 41,577      $ 185,959  

ADJUSTMENTS TO NET (LOSS) INCOME:

            

Inventory step-up charges

      1,238        —         1,238        —   

Acquisition and integration costs

      934        2,111        5,861        9,514  

Restructuring costs(3)

      8,188        —         32,200        —   

Contingent consideration

      697        (17,125 )       (30,569 )       (28,729 ) 

Intangible amortization

      8,651        7,304        30,981        27,016  

Loss on extinguishment of debt

      12,676        —         12,676        —   

Non-cash interest expense

      620        —         620        —   

Amortization of debt issuance costs(4)

      6,702        455        8,075        1,815  

Foreign currency impact of certain intercompany loans (5)

      (7,743 )       —         (7,743 )       —   

Tax effect of non-GAAP charges

      12,278        (2,402 )       3,485        (7,002 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

ADJUSTED NET INCOME (NON-GAAP)

    $ 18,753      $ 39,072      $ 98,401      $ 188,573  
  

 

 

     

 

 

     

 

 

     

 

 

  

Reconciliation of GAAP (Loss) Earnings Per Share to Adjusted Earnings Per Share (Non-GAAP)

 

     Three Months Ended
December 31,		      Twelve Months Ended
December 31,		  
     2023      2022      2023      2022  

GAAP (LOSS) EARNINGS PER SHARE - DILUTED(6)

    $ (0.46 )     $ 0.85      $ 0.74      $ 3.24  

ADJUSTMENTS TO (LOSS) EARNINGS PER SHARE - DILUTED:

            

Inventory step-up charges

      0.02        —         0.02        —   

Acquisition and integration costs

      0.02        0.04        0.10        0.17  

Restructuring costs(3)

      0.15        —         0.57        —   

Contingent consideration

      0.01        (0.30 )       (0.54 )       (0.50 ) 

Intangible amortization

      0.15        0.13        0.55        0.47  

Loss on extinguishment of debt

      0.22        —         0.22        —   

Non-cash interest expense

      0.01        —         0.01        —   

Amortization of debt issuance costs(4)

      0.12        0.01        0.14        0.03  

Foreign currency impact of certain intercompany loans (5)

      (0.14 )       —         (0.14 )       —   

Tax effect of non-GAAP charges

      0.22        (0.04 )       0.06        (0.12 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED(6)

    $ 0.33      $ 0.68      $ 1.75      $ 3.28  
  

 

 

     

 

 

     

 

 

     

 

 

  

Totals may not add due to rounding.

            

 

9

Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA (Non-GAAP)

 

     Three Months Ended
December 31,		      Twelve Months Ended
December 31,		  
     2023      2022      2023      2022  

GAAP NET (LOSS) INCOME

    $ 25,488 )     $ 48,729      $ 41,577      $ 185,959  

ADJUSTMENTS:

            

Investment income

      (6,023 )       (4,016 )       (24,135 )       (6,978 ) 

Interest expense

      1,138        270        1,951        1,162  

Amortization of debt issuance costs

      6,702        455        8,075        1,815  

Income tax (benefit) provision

      16,731        4,257        22,555        33,181  

Depreciation

      8,464        7,049        36,994        23,859  

Intangible amortization(7)

      8,679        7,331        31,091        27,126  
  

 

 

     

 

 

     

 

 

     

 

 

  

EBITDA

      10,203        64,075        118,108        266,124  

OTHER ADJUSTMENTS:

            

Inventory step-up charges

      1,238        —         1,238        —   

Acquisition and integration costs

      934        2,111        5,861        9,514  

Restructuring (3)(8)

      8,188        —         28,384        —   

Contingent consideration

      697        (17,125 )       (30,569 )       (28,729 ) 

Loss on extinguishment of debt

      12,676        —         12,676        —   

Foreign currency impact of certain intercompany loans (5)

      (7,743 )       —         (7,743 )       —   
  

 

 

     

 

 

     

 

 

     

 

 

  

ADJUSTED EBITDA (NON-GAAP)

    $ 26,193      $ 49,061      $ 127,955      $ 246,909  
  

 

 

     

 

 

     

 

 

     

 

 

  

Reconciliation of GAAP Cost of Sales to Adjusted Cost of Sales (Non-GAAP)

 

     Three Months Ended
December 31,		      Twelve Months Ended
December 31,		  
     2023      2022      2023      2022  

GAAP COST OF SALES

    $ 88,136      $ 90,700      $ 353,922      $ 345,830  

ADJUSTMENT TO COST OF SALES:

            

Inventory step-up charges

      (1,238 )       —         (1,238 )       —   

Acquisition and integration costs

      (6 )       (33 )       (39 )       (1,234 ) 

Restructuring(3)

      (7,675 )       —         (30,386 )       —   
  

 

 

     

 

 

     

 

 

     

 

 

  

ADJUSTED COST OF SALES (NON-GAAP)

    $ 79,217      $ 90,667      $ 322,259      $ 344,596  
  

 

 

     

 

 

     

 

 

     

 

 

  

Reconciliation of GAAP R&D Expense to Adjusted R&D Expense (Non-GAAP)

 

     Three Months Ended
December 31,		      Twelve Months Ended
December 31,		  
     2023      2022      2023      2022  

GAAP R&D EXPENSE

    $ 10,285      $ 11,113      $ 42,722      $ 43,936  

ADJUSTMENT TO R&D EXPENSE:

            

Acquisition and integration costs

      (2 )       (92 )       5        (658 ) 

Restructuring(3)

      (81 )       —         (116 )       —   
  

 

 

     

 

 

     

 

 

     

 

 

  

ADJUSTED R&D EXPENSE (NON-GAAP)

    $ 10,202      $ 11,021      $ 42,611      $ 43,278  
  

 

 

     

 

 

     

 

 

     

 

 

  

 

10

Reconciliation of GAAP SG&A Expense to Adjusted SG&A Expense (Non-GAAP)

 

     Three Months Ended
December 31,		      Twelve Months Ended
December 31,		  
     2023      2022      2023      2022  

GAAP SG&A EXPENSE

    $ 57,512      $ 53,237      $ 218,113      $ 215,829  

ADJUSTMENTS TO SG&A EXPENSE:

            

Acquisition and integration costs

      (925 )       (1,986 )       (5,826 )       (7,361 ) 

Restructuring(3)

      (432 )       —         (1,698 )       —   

Intangible amortization

      (8,651 )       (7,304 )       (30,981 )       (27,016 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

ADJUSTED SG&A EXPENSE (NON-GAAP)

    $ 47,504      $ 43,947      $ 179,608      $ 181,452  
  

 

 

     

 

 

     

 

 

     

 

 

  

Reconciliation of GAAP Net Income Guidiance to Adjusted Net Income (Non-GAAP) Guidance

 

     Twelve months ending December 31, 2024  
     Low End      High End  

GUIDANCE ON GAAP NET INCOME

    $ 26,000      $ 30,000  

ADJUSTMENTS TO GUIDANCE ON NET INCOME:

      

Acquisition and integration costs

      4,672        4,672  

Non-cash interest expense

      13,745        13,745  

Anticipated pre-tax amortization of acquisition-related intangible assets

      34,617        34,617  

Amortization of debt issuance costs

      1,887        1,887  

Contingent consideration

      11,000        11,000  

Tax effect of non-GAAP charges

      (11,751 )       (11,751 ) 

Guidance rounding adjustment

      (170 )       (170 ) 
  

 

 

     

 

 

  

GUIDANCE ON ADJUSTED NET INCOME (NON-GAAP)

    $ 80,000      $ 84,000  
  

 

 

     

 

 

  

Totals may not add due to rounding.

Reconciliation of GAAP Earnings Per Share Guidance to Adjusted Earnings Per Share (Non-GAAP) Guidance

 

     Twelve months ending December 31, 2024  
     Low End      High End  

GUIDANCE ON EARNINGS PER SHARE - DILUTED

    $ 0.46      $ 0.53  

ADJUSTMENTS TO GUIDANCE ON EARNINGS PER SHARE - DILUTED:

      

Acquisition and integration costs

      0.08        0.08  

Non-cash interest expense

      0.24        0.24  

Anticipated pre-tax amortization of acquisition-related intangible assets

      0.61        0.61  

Amortization of debt issuance costs

      0.03        0.03  

Contingent consideration

      0.19        0.19  

Tax effect of non-GAAP charges

      (0.21 )       (0.21 ) 

Guidance rounding adjustment

      (0.00 )       (0.00 ) 
  

 

 

     

 

 

  

GUIDANCE ON ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED

    $ 1.42      $ 1.49  
  

 

 

     

 

 

  

Totals may not add due to rounding.

 

11

FOOTNOTES FOR ALL TABLES ABOVE:

 

(1) 

Base revenue excludes COVID-related revenue and excludes acquisition-related revenue contribution in current periods for which there was no prior year comparables.

(2) 

Prior year acquisition revenue moved to “Base” for current year vs. prior year comparative purposes.

(3) 

In July 2023, we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our operations. In addition to the initial efforts contemplated in July, the Company continued further restructuring activities during the three months ended December 31, 2023. These activities in the fourth quarter primarily included the adjustment of finished goods and raw material inventory balances down to their net realizable value from continued evaluation of the analyses started in the third quarter, such as shelf-life stability tests. Where demand has reduced, the value of this inventory, mostly secured during the COVID-19 period, exceeded the projected requirements to be used before reaching their expiration date. In addition, restructuring activities included costs related to the consolidation of a portion of our manufacturing facilities between certain U.S. locations and severance & employee related costs.

(4) 

The twelve months ended December 31, 2022 represented amortization of debt issuance costs for the period April 1, 2022 to December 31, 2022 in addition to the amortization of debt issuance costs for the period March 5, 2022 to March 31, 2022 after the Second Supplemental Indenture was filed. Debt issuance cost for the period January 1, 2022 to March 4, 2022 were already reflected in the GAAP net income per share - diluted EPS under the if-converted method of calculating diluted EPS for the twelve months ended December 31, 2022.

(5) 

During the fourth quarter of 2023 we recorded foreign currency gains on certain intercompany loans of $7,743. The impact was recorded to the Other income (expenses), net line item within the Condensed Consolidated Statements of Operations.

(6) 

GAAP loss per share - diluted for the three months ended December 31, 2023, was determined excluding the effect of 626,847 shares of dilutive shares as the impact of such shares would have been antidilutive due to the net loss for the period, while the adjusted earnings per share - diluted for the same period was determined based upon diluted shares of 56,442,512 shares.

(7) 

Includes amortization of milestone payments in accordance with GAAP of $28 for the three months ended December 31, 2023 and 2022 and $111 for the twelve months ended December 31, 2023 and 2022.

(8) 

Excludes $3,816 of accelerated depreciation related to the Restructuring Plan for the twelve months ended December 31, 2023. This amount is included in the depreciation line item of this table.

# # #

 

12

EX-101.SCH 3 rgen-20240221.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rgen-20240221_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 rgen-20240221_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g742672g0221045129516.jpg GRAPHIC begin 644 g742672g0221045129516.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 21, 2024
Cover [Abstract]  
Entity Registrant Name REPLIGEN CORP
Amendment Flag false
Entity Central Index Key 0000730272
Document Type 8-K
Document Period End Date Feb. 21, 2024
Entity Incorporation State Country Code DE
Entity File Number 001-14656
Entity Tax Identification Number 04-2729386
Entity Address, Address Line One 41 Seyon Street
Entity Address, Address Line Two Bldg. 1
Entity Address, Address Line Three Suite 100
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02453
City Area Code (781)
Local Phone Number 250-0111
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol RGEN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d742672d8k.htm rgen-20240221.xsd rgen-20240221_lab.xml rgen-20240221_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d742672d8k.htm": { "nsprefix": "rgen", "nsuri": "http://www.repligencorp.com/20240221", "dts": { "inline": { "local": [ "d742672d8k.htm" ] }, "schema": { "local": [ "rgen-20240221.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "rgen-20240221_lab.xml" ] }, "presentationLink": { "local": [ "rgen-20240221_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-21_to_2024-02-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d742672d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-21_to_2024-02-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d742672d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.repligencorp.com//20240221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-24-040727-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-040727-xbrl.zip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end XML 18 d742672d8k_htm.xml IDEA: XBRL DOCUMENT 0000730272 2024-02-21 2024-02-21 REPLIGEN CORP false 0000730272 8-K 2024-02-21 DE 001-14656 04-2729386 41 Seyon Street Bldg. 1 Suite 100 Waltham MA 02453 (781) 250-0111 false false false false Common Stock, par value $0.01 per share RGEN NASDAQ false